Meta Pixel

News and Announcements

Armstrong Corporate Capital Limited (ACCL) – CEO Interview

  • Published April 29, 2014 9:27AM UTC
  • Publisher Wholesale Investor
  • Categories Executive Interviews

ACCL is an established motor vehicle investment scheme that provides strong returns for sophisticated investors seeking benchmark rates at a significant premium to retail and public sector super funds.

ACCL’s Motor Vehicle Investment Fund, with over $10M funds under management, focuses on alternative vehicle finance solutions with a growing portfolio of mid range vehicles valued between $30,000 to $50,000 purchased from wholesale commercial borrowers. The investment is offered as a 24 or 36 month debenture.

With strong risk management systems in place, ACCL is able to offer strong returns to investors whilst managing and mitigating the risk of borrowers. This is underpinned by continuing strong demand for financing of quality second hand vehicles has led to the expansion of this funding program.

ACCL’s is guided by experience Board and Management with the relevant executive experience to manage this fund and achieve consistent market outperformance – including the current Country Head of NAB China, a National Sales Manager for Bankwest Victoria, and CFO of Metallica and Metro Coal. Each board member is a shareholder with funds invested demonstrating their commitment to the business model.

Capital Insights
What is a Wholesale Investor in Australia? Complete 2026 Guide

What is a Wholesale Investor in Australia? A wholesale investor is an individual or entity that meets specific financial thresholds set out in the Corporations Act 2001 (Cth), qualifying them to access investment opportunities that are not available to general retail investors. These include private equity rounds, venture capital deals, pre-IPO placements, alternative funds, and […]

Capital Insights
Why the 20-Year Hold Is the Secret to Australian Life Sciences Returns

Australia represents 0.3% of the world’s population. Yet it generates more than 3% of global research output. Cochlear implants. Wi-Fi. The HPV vaccine. These are not statistical anomalies. They are proof points of a structural advantage that Australia has failed to capitalise on. The country has a world-class research base. But it watches companies scale […]

Join over 45,000+ sophisticated investors

Join Now